Clinical Trial Update: Clenbuterol to Target DUX4 in FSHD [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is ongoing to test clenbuterol as a therapy targeting DUX4 in facioscapulohumeral muscular dystrophy (FSHD) and is currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Facioscapulohumeral Muscular Dystrophy

Drugs mentioned

• Clenbuterol

Snippet

Sponsor: Jeffrey Statland | Conditions: Muscular Dystrophy, Facioscapulohumeral | Phase 1 | Status: RECRUITING